Discover. Innovate. Deliver.

Delivering on the Promise
of Cellular Therapeutics

BrainStorm is a leader in developing innovative autologous cellular therapies
for highly debilitating neurodegenerative diseases.

LEARN MORE

Phase 3 Pivotal Trial in ALS is Now Enrolling at 6 U.S. Sites

Phase 2 Trial in Progressive MS is Now Enrolling

OUR MISSION

BrainStorm is dedicated to defeating neurodegenerative diseases using an innovative, best-in-class, autologous cellular therapeutic technology platform, termed NurOwn®.

NUROWN® TECHNOLOGY PLATFORM

Play Video

BrainStorm’s autologous MSC-NTF cell therapy is investigational and not FDA approved.

Defining a new class of autologous cellular therapeutics

Grounded in breakthrough scientific innovation and focused on unmet medical need, BrainStorm is building a best-in-class platform, NurOwn®, for production of commercial-ready MSC-NTF cells to treat highly debilitating neurodegenerative diseases that currently have limited treatment options.

WHAT WE DO

BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage, publicly-traded biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases.

BrainStorm’s autologous MSC-NTF cell therapy has received Fast Track designation from the U.S. Food and Drug Administration (U.S. FDA) in amyotrophic lateral sclerosis (ALS) and has additionally been granted Orphan Status by the U.S. FDA and the European Medicines Agency (EMA).

BrainStorm is enrolling a phase 3 pivotal trial using repeat-administration of autologous MSC-NTF cells in ALS in the United States. Enrollment completion is anticipated in the first half of 2019 and will enable a Biologics License Application (BLA) filing for U.S. FDA approval in ALS.

BrainStorm is now enrolling a phase 2 study of autologous MSC-NTF cells in patients with progressive multiple sclerosis (MS). Learn more.
Scroll to Top